Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage

Journal of Translational Medicine

Volumn 14, Issue 1, 2016, Pages

  Canossi, Angelica ^a   Aureli, Anna ^a   Beato, Tiziana ^a   Rossi, Piero ^b   Franceschilli, Luana ^b   Sanctis, Flavio ^b   Sileri, Pierpaolo ^b   Di Lorenzo, Nicola ^b   Buonomo, Oreste ^b   Lauro, Davide ^b   Venditti, Adriano ^b   Sconocchia, Giuseppe ^a  

^a INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

CD16A; Colorectal carcinoma; CRC; FCGR3A genotypes; Genetic risk; KIR; NK

Indexed keywords

FC RECEPTOR; FC RECEPTOR IIIA; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; UNCLASSIFIED DRUG; FCGR3A PROTEIN, HUMAN; LIGAND;

AGED; ARTICLE; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CD16A GENE; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HIGH RISK POPULATION; HUMAN; KIR GENE; KIR2DL2 GENE; KIR2DS2 GENE; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK REDUCTION; SEQUENCE BASED TYPING; ALLELE; COLORECTAL TUMOR; DEMOGRAPHY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; ITALY; METABOLISM; PATHOLOGY; RISK FACTOR;

AGED; ALLELES; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DEMOGRAPHY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HLA-C ANTIGENS; HUMANS; ITALY; LIGANDS; MALE; NEOPLASM STAGING; RECEPTORS, IGG; RECEPTORS, KIR; RISK FACTORS;

EID: 84988349430     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-016-1001-y     Document Type: Article

References (52)

1. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-4.
2. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(Suppl 1):93-103.
3. Weixler B, Cremonesi E, Sorge R, Muraro MG, Delko T, Nebiker CA, et al. OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer. Oncotarget. 2015;6(Suppl 35):37588-99.
4. Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol. 2012;167(Suppl 2):195-205.
5. Halvorsen EC, Mahmoud SM, Bennewith KL. Emerging roles of regulatory T cells in tumor progression and metastasis. Cancer Metastasis Rev. 2014;33(Suppl 4):1025-41.
6. Droeser RA, Hirt C, Eppenberger-Castori S, Zlobec I, Viehl CT, Frey DM. High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. PLoS ONE. 2013;8(Suppl 5):e64814.
7. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res. 2007;13(Suppl. 5):1472-9.
8. Hirt C, Eppenberger-Castori S, Sconocchia G, Iezzi G, Tornillo L, Terracciano L, et al. Colorectal cancer infiltration by myeloperoxidase positive neutrophil granulocytes is associated with favorable prognosis. Oncoimmunology. 2013;2(Suppl 10):e25990.
9. Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, et al. Tumor infiltration by FcgammaRIII (CD16) + myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer. 2011;128:2663-72.
10. Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, et al. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer. 2010;126(Suppl. 11):2635-43.
11. Coppola A, Arriga R, Lauro D, Del Principe MI, Buccisano F, Maurillo L, et al. NK cell inflammation in the clinical outcome of colorectal carcinoma. Front Med (Lausanne). 2015;2:33.
12. Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC. Melanoma cells inhibit NK cell functions-letter. Cancer Res. 2012;72(Suppl 20):5428-9.
13. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997;79(Suppl. 12):2320-8.
14. Menon AG, van Janssenrhijn CM, Morreau H, Putter H, Tollenaar RA, vande Velde CJ, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest. 2004;84(Suppl 4):493-501.
15. Desbois M, Rusakiewicz S, Locher C, Zitvogel L, Chaput N. Natural killer cells in non-hematopoietic malignancies. Front Immunol. 2012;3:395.
16. Sconocchia G, Eppenberger-Castori S, Spagnoli GC, Tornillo L, Droeser R, Caratelli S, et al. NK cells and T cells cooperate during the clinical course of colorectal cancer. Oncoimmunology. 2014;3:e952197-0.
17. Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer. 2006;118(Suppl. 1):6-10.
18. Joncker NT, Fernandez NC, Treiner E, Vivier E, Raulet DH. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J Immunol. 2009;182(Suppl 8):4572-80.
19. Iwaszko M, Bogunia-Kubik K. Clinical significance of the HLA-E and CD94/NKG2 interaction. Arch Immunol Ther Exp (Warsz). 2011;59(5):353-67.
20. Biassoni R, Falco M, Cambiaggi A, Costa P, Verdiani S, Pende D, et al. Amino acid substitutions can influence the natural killer (NK)-mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the target cell protection from lysis mediated by "group 2' or "group 1' NK clones. J Exp Med. 1995;182(Suppl 2):605-9.
21. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005;5(Suppl 3):201-14.
22. Moretta L, Montaldo E, Vacca P, Del Zotto G, Moretta F, Merli P, Locatelli F, Mingari MC. Human natural killer cells: origin, receptors, function, and clinical applications. Int Arch Allergy Immunol. 2014;164(Suppl. 4):253-64.
23. Benson DM Jr, Caligiuri MA. Killer immunoglobulin-like receptors and tumor immunity. Cancer Immunol Res. 2014;2(Suppl 2):99-104.
24. Kulkarni S, Martin MP, Carrington M. The Yin and Yang of HLA and KIR in human disease. Semin Immunol. 2008;20(Suppl 6):343-52.
25. Middleton D, Vilchez JR, Cabrera T, Meenagh A, Williams F, Halfpenny I, et al. Analysis of KIR gene frequencies in HLA class I characterised bladder, colorectal and laryngeal tumours. Tissue Antigens. 2007;69(Suppl 3):220-6.
26. Al OS, Middleton D, Marshall E, Porter D, Xinarianos G, Raji O, et al. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Hum Immunol. 2010;71(Suppl 10):976-81.
27. De Re V, Caggiari L, De Zorzi M, Talamini R, Racanelli V, Andrea M. Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. PLoS ONE. 2014;9(Suppl 1):e84940.
28. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol. 2013;6:1.
29. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc γRIIIa-158 V/V and V/F polymorphism. Blood. 2007;110(Suppl. 7):2561-4.
30. Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2010;32(Suppl 3):437-53.
31. Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol. 2013;4:76.
32. Caggiari L, Toffoli G, De Re V, Orzes N, Spina M, De Zorzi M, et al. KIR/HLA combination associated with the risk of complications in celiac disease. Int J Biol Mark. 2011;26(Suppl 4):221-8.
33. Fasano ME, Rendine S, Pasi A, Bontadini A, Cosentini E, Carcassi C, et al. The distribution of KIR-HLA functional blocks is different from north to south of Italy. Tissue Antigens. 2014;83(Suppl 3):168-73.
34. Middleton D, Gonzelez F. The extensive polymorphism of KIR genes. Immunology. 2010;129(Suppl 1):8-19.
35. Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology. 2011;132(Suppl 3):315-25.
36. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. FcgammaRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90(Suppl 3):1109-14.
37. Guo SW, Thompson ES. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics. 1992;48(Suppl 2):361-72.
38. Beksac K, Beksac M, Dalva K, Karaagaoglu E, Tirnaksiz MB. Impact of "killer immunoglobulin-like receptor/ligand" genotypes on outcome following surgery among patients with colorectal cancer: activating KIRs are associated with long-term disease free survival. PLoS ONE. 2015;10(Suppl 7):e0132526.
39. Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B, Vyas YM. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol. 2003;171(Suppl 12):6891-9.
40. Uhrberg M, Valiante NM, Young NT, Lanier LL, Phillips JH, Parham P. The repertoire of killer cell Ig-like receptor and CD94:NKG2A receptors in T cells: clones sharing identical alpha beta TCR rearrangement express highly diverse killer cell Ig-like receptor patterns. J Immunol. 2001;166(Suppl 6):3923-32.
41. Hollenbach JA, Ladner MB, Saeteurn K, Taylor KD, Mei L, Haritunians T, et al. Susceptibility to Crohn's disease is mediated by KIR2DL2/KIR2DL3 heterozygosity and the HLA-C ligand. Immunogenetics. 2009;61(Suppl 10):663-71.
42. Moretta L, Montaldo E, Vacca P, Del Zotto G, Moretta F, Merli P, et al. Human natural killer cells: origin, receptors, function, and clinical applications. Int Arch Allergy Immunol. 2014;164(Suppl 4):253-64.
43. Carrington M, Wang S, Martin MP, Gao X, Schiffman M, Cheng J, et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med. 2005;201(Suppl 7):1069-75.
44. Butsch KM, Martin M, Gao X, Fuksenko T, Chen CJ, Cheng YJ, et al. Variation of the killer cell immunoglobulin-like receptors and HLA-C genes in nasopharyngeal carcinoma. Cancer Epidemiol Biomark Prev. 2005;14(Suppl 11 Pt1):2673-7.
45. Sconocchia G, Eppenberger-Castori S, Zlobec I, Karamitopoulou E, Arriga R, Coppola A, et al. HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. Neoplasia. 2014;16(Suppl 1):31-42.
46. Dellachiesa M, Vitale M, Carlomagno S, Ferlazzo G, Moretta L, Moretta A. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur J Immunol. 2003;33(Suppl 6):1657-66.
47. Pandey JP, Namboodiri AM. Genetic variants of IgG1 antibodies and FcgammaRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells. Oncoimmunology. 2014;3(1):e27317.
48. Chapel H, Geha R, Rosen F. Primary immunodeficiency diseases: an update. Clin Exp Immunol. 2003;132(Suppl 1):9-15.
49. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson C, et al. Cetuximab-activated natural killer (NK) and dendritic cells (DC) collaborate to trigger tumor antigen-specific T cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19(7):1858-72.
50. de Vries E, Koene HR, Vossen JM, Gratama JW, von dem Borne AE, Waaijer JL, et al. Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood. 1996;88(Suppl 8):3022-7.
51. Vance BA, Huizinga TW, Wardwell K, Guyre PM. Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte/natural killer cells. J Immunol. 1993;151(Suppl 11):6429-39.
52. de Haas M, Koene HR, Kleijer M, de Vries E, Simsek S, van Tol MJ, et al. A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa. J Immunol. 1996;156(Suppl 8):2948-55.